Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
By M. Benn, G. Watts, A. Tybjaerg-hansen, Børge G. Nordestgaard. Journal of Clinical Endocrinology and Metabolism, 2012
615 citations recorded by the source corpus.
Subfields: Emergency Medicine, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/50062ca87c5294848155fe198e604f7fa60f4906
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
- I. Graham
- Børge G. Nordestgaard
- Jan Boren
- A. Tybjærg-Hansen
- Marja-Riitta Taskinen
- M. Chapman
- Alberico L. Catapano
In Surgery
- I. Graham
- Jan Boren
- A. Tybjærg-Hansen
- Børge G. Nordestgaard
- M. Chapman
- Marja-Riitta Taskinen
- Alberico L. Catapano
Citations in the corpus
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013, background): “5 points) was 1/200 (Figure 2).(10) Interestingly, prevalences for definite or probable FH were similar for women and men below age 60; in”
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “The frequency of HeFH in the population has earlier been estimated at 1/500; however, recent studies from whole populations suggest that the frequency is higher, in some populations as high as 1/137.(297) Based on extrapolations from available data, the frequency of HeFH can be estimated to be betwe”
- Familial hypercholesterolemia (2011, neutral): “An analysis using a modified version of the Dutch Lipid Clinic (DLC) criteria (9) applied to”